INGEVITY CORPORATION (NGVT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $77.32, INGEVITY CORPORATION (NGVT) is priced for -4.2% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/NGVT

Headline

FieldValue
TickerNGVT
CompanyINGEVITY CORPORATION
Current price$77.32/sh
CompositionPerformance Materials segment 52% / Performance Chemicals segment 34% / Advanced Polymer Technologies segment 14%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Implied growth-4.2%
Multiple paid9x operating income

Solve inputs: computed at a 10% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~4.4pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.86σ
cohort percentile (of 77 peers)5
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset3.62x4expensive
Earnings1.79x4expensive
Relative0
Growth0.88x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=11)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$104.570.74xyesFCF base $0.2B, growth 9% (input: historical growth), terminal g 4.0%, WACC 8.9%, 6yr projection
DCF Exit MultipleGrowth$88.340.88xyesExit EV/EBITDA: 118.7x / 120.7x / 122.7x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelativenoP/E 24.57x (blended: static sector reference 14x + trailing (TTM) 49x), scenarios: 20.5x / 24.6x / 28.6x (bear / base = reference held flat / bull), EV/EBITDA 17.6x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$16.984.55xyesBV/sh $1.36, ROE (TTM) 115.1%, ke 9.3%
Two-Stage Excess ReturnAsset$150.600.51xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$63.931.21xyesRev $1.1B, growth 9% (input: historical growth; tapered), Terminal P/S: 2.0x / 2.4x / 2.8x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$108.910.71xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.45B × (1−21%) / WACC 8.9% → EPV (no growth)
Residual IncomeAsset$28.832.68xyesBV $1.36 + 5yr PV of (ROE (TTM) 115.1% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$6.8111.35xyes√(22.5 × EPS $1.51 × BVPS $1.36) — Graham's conservative floor
EV/EBITDA RelativeRelativenoEBITDA $0.02B × sector EV/EBITDA 8.0x
FCF YieldEarnings$46.311.67xyesFCF $154.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$40.391.91xyesSBC-adj FCF $0.14B (FCF $0.15B − SBC $0.02B) capitalized at Kₑ
Ben Graham FormulaEarnings$1.2760.88xyesEPS $1.51 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAssetno
P/Sales SectorRelativenoRevenue $1.09B × sector P/S 1.5x
PEG Fair ValueRelativeno
Earnings YieldEarnings$16.324.74xyesEPS $1.51 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Performance Materialsoperatingenterprise$606.9m$5.2b indicative EV subtotalindicative enterprise value
Performance Chemicalsoperatingenterprise$400.5mwithheldunresolved no unit value
Advanced Polymer Technologiesoperatingenterprise$160.2m$514.0m indicative EV subtotalindicative enterprise value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$1.1b
Net debt / NOPAT (after-tax)3.36x
Net debt / operating income (pre-tax)2.63x
Interest coverage5.3x
Share count CAGR (buyback)-2.3%
Burning cashno

Bullet Takeaways

Bull Case

Look first at how far the price sits below where the methods land, because that gap is the bull case. The earnings-power lens and the cash-flow methods both reach today's price or sit above it, which means the market is paying roughly what the demonstrated profit and a modest growth path justify, not a premium on top of them. Reading the price backward makes the point sharper: at today's level the market is pricing operating profit to shrink about 3% a year for five years. The bull case does not need growth to win. It needs Ingevity to simply not decline as much as the price assumes.

The reason that is plausible is the quality of the core franchise. Ingevity operates in three segments, and its Performance Materials business makes the activated carbon that captures gasoline vapor in vehicle fuel systems. The filing describes the mechanism plainly: captured vapors "are largely purged from the activated carbon and re-directed to the engine where they are used as supplemental power for the vehicle." That is a specified, regulation-driven product with high barriers, and it is what holds the consolidated operating margin near 34%. Profitability stayed resilient through a noisy quarter, with adjusted earnings margin around 35.5%, which is the signal that the core economics are intact even while the company reshapes the rest.

Management is using the cash and the portfolio actively, which is the second pillar. Ingevity has been shrinking its share count, down about 2% a year, and it completed a series of divestitures, selling the Ozark Materials road-markings line, the North Charleston crude tall oil refinery, and most of its industrial specialties product line. These were the lower-margin, more cyclical pieces, and shedding them concentrates the company on its better businesses. Pricing actions in Performance Materials and pavement technologies, helped by foreign exchange, lifted first-quarter revenue 4.1% to $258 million, ahead of expectations. A buyer at today's price is paying for a high-margin specialty franchise priced as if it slowly fades, with management actively pruning the weak parts and buying back stock.

Bear Case

The competitive threat to Ingevity's best business is not a rival chemical maker, it is the car itself changing. Performance Materials earns its margin from activated carbon that captures gasoline vapor, and that demand exists only because internal-combustion vehicles release those vapors. The company's own filing names the substitution directly: "multiple OEMs are using sealed tanks in certain subsets of their vehicles to comply with the strict emission regulations" such as the U.S. Tier 3 and LEV III standards. Sealed tanks need less carbon, and electric vehicles need none. The single most profitable segment is tied to a powertrain the industry is slowly engineering away from, and that erosion is structural, not cyclical.

Performance Chemicals, the other major segment, shows a different kind of fragility: thin and volatile margins. In the first quarter the segment's adjusted earnings margin fell to around 1%, which management attributed to lower plant utilization in road markings and higher supply-chain and overhead costs. The business also rests on commodity inputs whose prices the company does not control. The filing lists key raw materials including "maleic anhydride, ethoxylates, amines, and acrylic emulsions" for Performance Chemicals, and notes that the prices of its tall-oil feedstocks track "actual and expected harvest rates, petroleum oil prices, and the biofuel market." When feedstock costs rise and utilization falls at the same time, a low-margin chemicals business swings quickly from profit to loss.

The valuation read is more nuanced than a simple cheap-or-rich verdict. The earnings-power and cash-flow methods support the price, but the peer-multiple comparison reads it as roughly 48% above where its specialty-chemicals peers trade. The price is paying about nine times operating income, which embeds a gentle decline rather than growth, so the bear is not arguing the stock is wildly overvalued. The bear is arguing the gentle-decline assumption could prove optimistic if Performance Materials erodes faster than expected and Performance Chemicals stays at razor-thin margins. Net debt sits near $987 million, about 2.5 times operating income, a manageable load for a profitable specialty maker but one that leaves less room if the better segment fades while the weaker one struggles to recover utilization.

Valuation

The price is making a quiet bet, and naming it changes how the stock reads. At today's level the market is paying about nine times operating income, which works out to pricing operating profit to decline roughly 3% a year for five years. This is not a growth stock priced for acceleration; it is a profitable specialty business priced as if it slowly shrinks. The framework reads that embedded assumption as within range of what is plausible, because the recent pace is consistent with what the company has delivered. The whole question is whether the decline the price assumes is too pessimistic, about right, or not pessimistic enough.

The methods split in a way that frames it as a value name rather than a growth bet. The earnings-power lens sits essentially at the price, and the cash-flow methods sit just above it, both saying the demonstrated profit and a modest path justify today's level. The peer-multiple comparison is the dissenter, placing the price around 48% above where the chosen specialty-chemicals peers trade. That spread is the tension: the absolute-value methods say the earnings support the price, while the relative lens says it looks dear next to its cohort. For a business undergoing a portfolio overhaul, the absolute methods deserve the heavier weight, because the peer set mixes companies with different segment economics and the comparison is sensitive to which peers are chosen.

Solvency is comfortable enough to keep the focus on the operating question. Net debt of about $987 million is roughly 2.5 times operating income, and trailing operating profit near $399 million on a 34% margin gives the company room to service it and keep buying back stock. Interest expense is not separately broken out in the latest filings, so a precise coverage figure is not available, but the leverage ratio and the margin profile point to a balance sheet that is not the binding constraint. The decisive variable is the durability of Performance Materials.

Catalysts

The portfolio reshaping is the catalyst that defines the next year. Ingevity completed the sale of its Ozark Materials road-markings product line, divested its North Charleston crude tall oil refinery, and sold the majority of its industrial specialties product line, shedding lower-margin and more cyclical operations to concentrate on its better businesses. How cleanly those exits flow through to a higher-margin, simpler company is the strategic milestone to watch.

The near-term operating picture is mixed and worth tracking by segment. First-quarter 2026 revenue rose 4.1% year over year to $258 million on pricing actions in Performance Materials and pavement technologies plus favorable foreign exchange, and adjusted earnings margin held around 35.5%. The soft spot was Performance Chemicals, where the adjusted earnings margin fell to about 1% on weak road-markings utilization and higher costs. Whether that segment's utilization recovers is the quarterly swing factor.

Guidance frames the full-year target. After updating its ranges for the road-markings divestiture, Ingevity reaffirmed 2026 net sales of $1.05 to $1.15 billion and adjusted earnings before interest, tax, depreciation and amortization of $370 to $395 million. Delivery against that range, paired with continued portfolio cleanup and share repurchases, is what the market will measure the repositioning against.

Peer Cohorts (Per Segment, With Filing Citations)

Performance Materials / Advanced Polymer Technologies (reported)

Performance Chemicals (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

company 10-K, fiscal 2024 · Ingevity Q1 2026 results

View the full interactive NGVT report on boothcheck